SR 95531 hydrobromide
(Synonyms: 克他命,Gabazine) 目录号 : GC10101SR 95531 氢溴酸盐 (Gabazine) 是 GABAA 受体上 GABA 结合位点的选择性拮抗剂 。
Cas No.:104104-50-9
Sample solution is provided at 25 µL, 10mM.
SR 95531 hydrobromide (Gabazine) to be a selective antagonist at the GABA binding sites on GABAA receptors [1]. SR 95531 hydrobromide partially inhibited direct activation of the receptor by the barbiturate pentobarbital and by the steroid alphaxolone, possibly by acting as an allosteric inhibitor of GABAA receptor channel opening [2].
SR 95531 hydrobromide had antagonist potency response against to the binding of GABA and recombination α1β2γ2S GABAA receptors, with the IC50 of 349 nM [1]. The competitive antagonist SR 95531 hydrobromide showed similar potency on both cell types with IC50's of 196 nM and 224 nM on α4β3γ2 receptors and α4β3δ receptors respectively [3]. In αTC1-9 cells, GABA (10 μmol/l) significantly suppressed glucagon secretion to ~50% of control levels, whereas in the presence of SR 95531 hydrobromide (10 μmol/l), exogenous GABA exerted no significant effect on glucagon secretion [4].
SR 95531 hydrobromide administered i.t. effectively attenuated antinociception induced by i.t. administered Dipsacus saponin C (DSC) [5].
References:
[1]. Iqbal F, Ellwood R, Mortensen M, et al. Synthesis and evaluation of highly potent GABAA receptor antagonists based on gabazine (SR-95531)[J]. Bioorganic & medicinal chemistry letters, 2011, 21(14): 4252-4254.
[2]. Ueno S, Bracamontes J, Zorumski C, et al. Bicuculline and gabazine are allosteric inhibitors of channel opening of the GABAA receptor[J]. Journal of Neuroscience, 1997, 17(2): 625-634.
[3]. Brown N, Kerby J, Bonnert T P, et al. Pharmacological characterization of a novel cell line expressing human α4β3δ GABAA receptors[J]. British journal of pharmacology, 2002, 136(7): 965-974.
[4]. Bailey S J, Ravier M A, Rutter G A. Glucose-dependent regulation of γ-aminobutyric acid (GABAA) receptor expression in mouse pancreatic islet α-cells[J]. Diabetes, 2007, 56(2): 320-327.
[5]. Suh H W, Song D K, Huh S O, et al. Antinociceptive mechanisms of Dipsacus saponin C administered intrathecally in mice[J]. Journal of ethnopharmacology, 2000, 71(1-2): 211-218.
SR 95531 氢溴酸盐 (Gabazine) 是 GABAA 受体上 GABA 结合位点的选择性拮抗剂 [1]。 SR 95531 氢溴酸盐部分抑制巴比妥类戊巴比妥和类固醇阿尔法索酮对受体的直接激活,可能是作为 GABAA 受体通道开放的变构抑制剂[2]。
SR 95531 hydrobromide 对 GABA 和重组 α1β2γ2S GABAA 受体的结合具有拮抗作用,IC50 为 349 nM [1]。竞争性拮抗剂 SR 95531 hydrobromide 对两种细胞类型显示相似的效力,对 α4β3γ2 受体和 α4β3δ 受体的 IC50 分别为 196 nM 和 224 nM [3]。在 αTC1-9 细胞中,GABA (10 μmol/l) 将胰高血糖素分泌显着抑制至对照水平的 50%,而在 SR 95531 氢溴酸盐 (10 μmol/l) 存在的情况下,外源性 GABA 对胰高血糖素分泌没有显着影响 < sup>[4].
SR 95531 氢溴酸盐给药于它。有效减弱 it 诱导的抗伤害作用给予续断皂甙 C (DSC) [5]。
Animal experiment [1]: | |
Animal models |
Male ICR mice |
Preparation Method |
Effects of 5-aminovaleric acid (5-AVA) and SR 95531 injected intrathecally (i.t.) on inhibition of the tail-flick response induced by DSC administered i.t. Saline (5 µl), 5-AVA (from 1 to 20 µg) or SR 95531 (from 0.1 to 2 ng) was pretreated i.t. 10 min before i.t. administration of DSC (30 µg) or vehicle. |
Dosage form |
injected intrathecally, 0.1 to 2 ng |
Applications |
SR 95531 attenuated i.t. administered DSC-induced inhibition of the tail-flick response in a dose-dependent manner. |
References: [1]: Suh H W, Song D K, Huh S O, et al. Antinociceptive mechanisms of Dipsacus saponin C administered intrathecally in mice[J]. Journal of ethnopharmacology, 2000, 71(1-2): 211-218. |
Cas No. | 104104-50-9 | SDF | |
别名 | 克他命,Gabazine | ||
化学名 | 4-(6-imino-3-(4-methoxyphenyl)pyridazin-1(6H)-yl)butanoic acid hydrobromide | ||
Canonical SMILES | COC1=CC=C(C(C=CC2=N)=NN2CCCC(O)=O)C=C1.Br | ||
分子式 | C15H17N3O3.HBr | 分子量 | 368.23 |
溶解度 | MeOH:PBS (pH 7.2); (1:1): 0.5 mg/ml,Methanol: 1 mg/ml | 储存条件 | Store at 4°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.7157 mL | 13.5785 mL | 27.1569 mL |
5 mM | 0.5431 mL | 2.7157 mL | 5.4314 mL |
10 mM | 0.2716 mL | 1.3578 mL | 2.7157 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >97.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet